Atlas Trials

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy

Clinical trial NCT04878107 · UNKNOWN

Trial details

NCT number
NCT04878107
Sponsor
Wuhan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2022-03-15
Primary completion
2022-10-01
Enrollment
88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.